Login to Your Account

Other News To Note

Thursday, December 22, 2011

Lycera Corp., of Ann Arbor, Mich., said it reached the first milestone under its research collaboration with Merck & Co. Inc., of Whitehouse Station, N.J., triggering an undisclosed milestone payment. The collaboration is focused on developing drug candidates that target T-helper 17 (Th17) cells, key mediators of inflammation, to treat autoimmune diseases such as rheumatoid arthritis, psoriasis, inflammatory bowel disease and multiple sclerosis. (See BioWorld Today, March 4, 2011.)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription